Investors / France / AdBio partners
AdBio partners
Venture capital · Paris, France · Europe
AdBio partners is a venture capital firm that invests in early-stage life sciences companies in Europe. It co-founds companies with scientific founders, provides initial funding, and offers hands-on operational support to portfolio companies.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechhealthcaretherapeuticsacademic researchearly stage
Your fit with AdBio partners
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsAdBio partners lists 17 checked portfolio companies on its own site and is named in 3 funding rounds. Its most frequent entry is Seed, 33% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 50% of its companies are based in France. It invests most often alongside Asabys Partners, Columbus Venture Partners and Jeito Capital.
Counts come from funding rounds that name AdBio partners, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not AdBio partners' whole history. Rounds on record name 3 companies; its own site lists 17. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 33% |
| Series A | 33% |
| Series B | 33% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 3 | 0 |
| '26 | 0 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 44th | 17 companies |
| Recent activity | 46th | 0 rounds in 12 months |
| Early stage | 64th | 33% of entries at pre-seed or seed |
| Evidence | 89th | 18% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 70th | 4 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Asabys Partners | 3 |
| Columbus Venture Partners | 2 |
| Jeito Capital | 2 |
| V-Bio Ventures | 2 |
| Advent Life Sciences | 1 |
| Bioqube Ventures | 1 |
| British Business Bank | 1 |
| Canaan | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers17100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare AdBio partners head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with AdBio partners| Date | Company | Stage |
|---|---|---|
| 17 Sept 2025 | Series B | |
| 8 Sept 2025 | Seed | |
| 24 Mar 2025 | Series A |
Round details for AdBio partners
Amounts, full round histories and every co-investor in AdBio partners' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
17 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases. | Healthcare & Biotech | Portfolio page | ||
| AndzonBio accelerates the industrial development of promising academic projects in life sciences. | Healthcare & Biotech | Portfolio page | ||
| AndzonBio1 targets core disease mechanisms to address underserved cardiovascular, renal, and metabolic conditions | Healthcare & Biotech | Portfolio page | ||
| AndzonBio2 develops early-stage therapies focused on neuroinflammation, a key driver of neurological and neurodegenerative diseases. | Healthcare & Biotech | Portfolio page | ||
| Arthex Biotech develops RNA medicine for diseases with unmet medical needs, including Myotonic Dystrophy. | Healthcare & Biotech | Sept 2025Series B | Page + round | |
| Astraveus develops cell therapies through the development of the Lakhesys Benchtop Cell Factory | Healthcare & Biotech | Portfolio page | ||
| Augustine Therapeutics develops novel HDAC6 inhibitors for the treatment of chronic diseases | Healthcare & Biotech | Mar 2025Series A | Page + round | |
| Cephagenix is focused on identifying and developing new effective migraine treatments | Healthcare & Biotech | Portfolio page | ||
| DiogenX is a preclinical stage biotech company committed to discovering and developing innovative biologics as new therapeutics options for diabetic patients. | Healthcare & Biotech | Portfolio page | ||
| Integra Therapeutics is committed to create new gene writing tools that help to improve the scope, efficiency and safety of advanced therapies. | Healthcare & Biotech | Sept 2025Seed | Page + round | |
| Kiji Therapeutics is an international biotech company dedicated to delivering a new era of IPSC-MSC engineered cell therapy for inflammatory diseases. | Healthcare & Biotech | Portfolio page | ||
| Orikine Bio develops precision-engineered, bi-specific cytokines to treat autoimmune and inflammatory diseases | Healthcare & Biotech | Portfolio page | ||
| SparingVision develops gene therapies for blinding retinal diseases. | Healthcare & Biotech | Portfolio page | ||
| Tenpoint Therapeutics develops treatments for presbyopia, cataracts, and geographic atrophy. | Healthcare & Biotech | Portfolio page | ||
| Thabor Therapeutics is developing a therapeutic antibody for the treatment of inflammatory mucosal diseases. | Healthcare & Biotech | Portfolio page | ||
| Tridek-One develops first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases | Healthcare & Biotech | Portfolio page | ||
| Urania Therapeutics develops treatments for genetic diseases and cancers caused by nonsense mutations. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- adbio.partners
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 24 Mar 2025
- Companies checked
- 17
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get AdBio partners' profile as data
Pull AdBio partners' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/adbio.partners
# also
GET /v1/firms/adbio.partners/portfolio
GET /v1/firms/adbio.partners/coinvestors
GET /v1/firms/adbio.partners/news